Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Today, Royal Bank of Canada raised its price target on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to $7.00 per share.
There are 5 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target price of $8.20 per share, a potential 125.90% upside.
Some recent analyst ratings include
- 10/15/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Oppenheimer
- 10/15/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) gets upgraded to Buy by Jefferies Financial Group with a price target of $8.00
- 10/10/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy ➝ Buy rating reiterated by LADENBURG THALM/SH SH with a $10.00 price target
- 10/13/2017-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Piper Jaffray Companies with a $2.00 price target
- On 10/15/2018 Badri N Dasu, Insider, sold 28,351 with an average share price of $5.00 per share and the total transaction amounting to $141,755.00.
- On 9/24/2018 Lawrence G Hamel, Insider, sold 6,953 with an average share price of $4.50 per share and the total transaction amounting to $31,288.50.
- On 8/7/2018 Mark G Edwards, Director, bought 5,300 with an average share price of $2.84 per share and the total transaction amounting to $15,052.00.
- On 8/7/2018 Vincent J. Angotti, CEO, bought 10,000 with an average share price of $2.90 per share and the total transaction amounting to $29,000.00.
- On 8/6/2018 Pamela P. Palmer, Insider, bought 37,000 with an average share price of $2.75 per share and the total transaction amounting to $101,750.00.
- On 8/6/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $2.75 per share and the total transaction amounting to $13,750.00.
- On 6/5/2018 Mark G Edwards, Director, bought 5,000 with an average share price of $3.35 per share and the total transaction amounting to $16,750.00.
About AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Recent Trading Activity for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Shares of AcelRx Pharmaceuticals Inc closed the previous trading session at 3,63 −0,52 12,53 % with shares trading hands.